The global Antiviral Immunoglobulin Market was valued at USD 4.6 Billion in 2022 and is expected to reach USD 10.9 Billion by 2033. By route of administration, the IV segment is projected to continue its growth momentum over the forecast period (2023 to 2033) with an anticipated compound annual growth rate (CAGR) of close to 7.4%.
This growth is driven by factors such as the increasing prevalence of viral infections, expanding healthcare infrastructure, and advancements in IV administration techniques.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 4.6 Billion |
| Market Value 2023 | USD 5.0 Billion |
| Market Value 2033 | USD 10.9 Billion |
| CAGR 2023 to 2033 | 8.2% |
| Market Share of Top 5 Countries | 63.1% |
| Key Market Players | Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc., Bayers, Baxalta Incorporated, Kedrion SPA, AstraZeneca PLC., Omrix Biopharma, Sanofi, Cangene corporation. |
Immunoglobulins have traditionally assisted in opsonization, bacteriolysis stimulation, and toxin neutralization in bacterial infections. In viral infections, immunoglobulins prevent the infection of uninfected cells, support antibody-directed cell-mediated cytotoxicity by natural killer cells, and neutralize viruses either alone or in conjunction with complement.
They offer a rapid, safe, and cost-effective approach to obtaining valuable information about an individual's health status.
Due to the global increase in immunosuppression caused by conditions such as AIDS, organ transplantation, tumors, autoimmune diseases, and the emergence of multidrug-resistant organisms, there is a renewed interest in the use of antibody preparations for preventing infections in high-risk populations.
Substantial research has demonstrated that therapies aiming to promote or enhance the immune response may be feasible and beneficial for immunocompromised individuals.
Overall, immunoglobulins play a crucial role in various aspects of immune defense, providing targeted protection against pathogens and contributing to the well-being of individuals, particularly those with compromised immune systems.
Explore FMI!
Book a free demo
The global market recorded a historic CAGR of 6.8% in the last 10 years from 2012 – 2022. The global antiviral immunoglobulins was around 4.7% of the overall USD 97.14 Billion of the global antivirals market in 2022.
The increasing prevalence of viral infections globally, including diseases such as HIV, hepatitis, and influenza, is a major driver for the antiviral immunoglobulin market. These infections impose a significant healthcare burden, necessitating a greater demand for antiviral treatments, including immunoglobulins.
As viral infections continue to impact populations worldwide, the need for effective antiviral therapies such as immunoglobulins is on the rise, driving the growth of the market.
According to the data published by CDC in 2021, 36,136 people received an HIV diagnosis in the United States and dependent areas. The annual number of new diagnoses decreased by 7% from 2017 to 2021.
The use of immunoglobulins provides targeted and specific immune responses against viral pathogens, making them essential in combating viral infections and managing their associated complications.
Improvements in healthcare infrastructure, particularly in developing countries, have led to better access to antiviral immunoglobulin therapies. This expansion of healthcare facilities, along with increasing affordability and availability of antiviral immunoglobulins, contributes to market growth.
Viral outbreaks, such as influenza or emerging infectious diseases like COVID-19, lead to a surge in demand for antiviral immunoglobulin products. Synthetic biology offers a solution to the challenges associated with traditional antibody generation methods.
A study conducted by Aaron Sato and published on February 5, 2020, highlighted how synthetic biology can address these issues, potentially leading to the development of novel medications through optimized antibodies.
Collaborative efforts in research, development, and commercialization can expand the market reach of antiviral immunoglobulin products and facilitate the exploration of new applications.
Improved healthcare access in developing countries presents an opportunity for market expansion, as these regions often face a higher burden of viral infections and have a growing middle-class population with increased healthcare spending capacity.
The overall economic growth of a country or region significantly influences the demand for antiviral immunoglobulin products. During periods of economic growth, healthcare spending tends to increase, driving the demand for antiviral treatments.
Strict regulatory requirements, encompassing safety and efficacy evaluations, pose significant challenges to the development and commercialization of antiviral immunoglobulin products.
The rigorous process of meeting these regulatory standards can be time-consuming and expensive, creating barriers to market entry and potentially restraining the demand for these products.
Compliance with regulatory guidelines ensures the safety and effectiveness of immunoglobulin therapies but can also prolong the product development timeline and increase costs. These factors can impact the accessibility, affordability, and availability of antiviral immunoglobulin treatments, thus limiting their demand in the market.
In some cases, there may be alternative treatments available for viral infections, such as antiviral medications or vaccines. These alternatives may offer convenience, cost-effectiveness, or targeted therapeutic benefits, leading to reduced demand for antiviral immunoglobulin therapies.
In the year 2022, the USA holds a dominant share of 88.7% in the North American market, and it is expected to grow at a CAGR of 8.4% during the forecasted years. The USA is known for having one of the highest healthcare costs globally.
However, this also facilitates widespread access and affordability for advanced medical therapies, including antiviral immunoglobulins. The increasing cost of healthcare drives the demand for innovative and effective treatments, thus expanding the market for antiviral immunoglobulin products.
The healthcare insurance system in the USA is complex, involving various commercial and governmental insurance companies. Fortunately, antiviral immunoglobulin therapy is often covered by these insurance policies, which improves patients' access to and affordability of these treatments.
The coverage provided by insurance companies eases the financial burden on patients, ensuring they can benefit from antiviral immunoglobulin therapies.
In 2022, China emerged as the dominant player in the East Asia market, contributing around USD 198.3 million.
With the world's largest population, China faces a significant disease burden, leading to an increased demand for medical supplies, including antiviral immunoglobulins. This presents a lucrative market opportunity for manufacturers and sellers of these products, given the substantial patient pool in the country.
In May 2023, a prominent health expert in China predicted a potential surge of 65 million weekly COVID-19 cases in the country by June. This surge is fuelled by the XBB strain, a respiratory disease that has been spreading in China for nearly six months.
With the virus still circulating and public immunity waning, there remains a possibility of the emergence of a new, more dangerous sub-variant. This ongoing situation further underscores the need for effective medical interventions such as antiviral immunoglobulins to address the challenges posed by the evolving viral landscape in China.
In 2022, Japan held a significant market share of around 57.3% in the East Asia market. Japan boasts highly skilled and well-trained healthcare professionals, including doctors, researchers, and technicians.
Additionally, Japan has one of the highest proportions of elderly individuals globally. This demographic factor necessitates the use of antiviral immunoglobulins to treat or prevent viral infections in older populations.
The aging population in Japan has resulted in an increased demand for healthcare products, including antiviral immunoglobulins, to cater to their specific medical needs. The Japanese population benefits from a well-developed and established healthcare system that provides exceptional medical care.
This advanced healthcare system creates an environment conducive to the production and utilization of antiviral immunoglobulin products, ensuring their accessibility and effectiveness in addressing the healthcare needs of the Japanese population.
The intravenous route of administration accounted for a significant market share of 52.3% in the global market in 2022. When administered intravenously, antiviral immunoglobulins can be rapidly and directly delivered into the bloodstream.
This route of administration offers enhanced bioavailability and a prompt response against infections compared to other methods such as oral or subcutaneous administration.
By delivering antiviral immunoglobulins intravenously, the effective targeting of the medication to the desired location is ensured, leading to improved efficacy and treatment outcomes. Intravenous administration allows healthcare professionals to precisely control the delivery of antiviral immunoglobulins to the patient.
They can accurately measure and adjust the dosage based on the individual patient's needs. This dose consistency contributes to optimal therapeutic results while minimizing the risk of under or overdosing.
Hospital pharmacies play a significant role in the antiviral immunoglobulin market, representing 42.5% of end users in 2022 and exhibiting a CAGR of 9.8% over the forecast period. Hospitals are often the primary healthcare facility patients turn to when they contract a viral illness.
In the hospital setting, intravenous administration of antiviral immunoglobulin is commonly employed for the treatment of patients with severe viral infections. This ensures close monitoring by medical staff and allows for prompt adjustments to the treatment plan based on the patient's response.
Hospitals possess the necessary infrastructure and expertise to administer these drugs intravenously, ensuring the safe and effective delivery of antiviral immunoglobulins to patients.
The population may become less in need of antiviral treatments due to population immunity brought on by high vaccination rates and prior diseases.
With technological advances in the pharmaceutical sector, Antiviral Immunoglobulin will be useful in countering viral infections.
Similarly, recent developments related to the company’s active in the antiviral immunoglobulin market have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East; and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Northern Africa and South Africa. |
| Key Market Segments Covered | Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Biotest AG; Baxter International Inc.; Octapharma AG; LFB Biotechnologies; Grifols SA; CSL Behring; China Biologics Products Inc.; Kedrion Biopharma; BDI Pharma Inc.; Bayers; Baxalta Incorporated; Kedrion SPA; AstraZeneca PLC.; Omrix Biopharma.; Sanofi; Cangene corporation |
| Report Coverage |
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is valued at USD 5 billion in 2023.
From 2012 to 2022, the market registered a CAGR of 6.8%.
The market shall reach USD 10.9 billion in 2033.
The market’s CAGR from 2023 to 2033 will be 7.4%.
In 2022, the USA held a share of 88.7% of the North American market.
Hyperammonemia Treatment Market Trends – Growth & Therapeutic Advances 2025 to 2035
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Antiviral Immunoglobulin Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
